Hyperlipidemia, the condition of having too many fats circulating in the blood, is the primary driver of atherosclerosis. The connection is not incidental or merely statistical: excess lipid particles physically enter the artery wall, get trapped there, and set off a chain of inflammation that builds the fatty plaques responsible for heart attacks and strokes. That much has been established through decades of research. But the details of how different lipid particles contribute, why some people with normal-looking cholesterol numbers still develop plaques, and what actually makes a plaque dangerous are more nuanced than a standard cholesterol panel suggests.
How Lipids Get Into the Artery Wall
The story starts with the inner lining of your arteries, a single-cell-thick barrier called the endothelium. Under normal conditions, this lining keeps blood components where they belong. But when levels of certain lipid-carrying particles are elevated, those particles begin crossing the endothelium and lodging in the tissue beneath it. The movement of LDL particles across this barrier is the initial step that kicks off the entire disease process.1PubMed Central. Transport of LDLs into the arterial wall: impact in atherosclerosis
Once these particles are underneath the endothelium, they tend to stick around. They bind to structural molecules in the artery wall, and this retention is what truly sets atherosclerosis in motion.2PubMed. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Particles that pass through without getting trapped do not cause lasting damage. It is the ones that stay, accumulating over time, that become the seeds of a plaque. This is why the total duration and intensity of lipid exposure matter so much: a person with moderately elevated cholesterol over decades can end up with more artery damage than someone whose levels spike briefly and come back down.
From Trapped Lipids to Inflammation
Trapped LDL particles do not just sit inertly in the artery wall. They become chemically modified, primarily through oxidation. Oxidized LDL is the real troublemaker. Its accumulation in the inner layer of the artery is what triggers the onset of the disease in earnest.3PubMed Central. Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis
Your immune system recognizes oxidized LDL as a threat. White blood cells called macrophages arrive and begin swallowing the modified particles. The problem is that the receptors macrophages use to take in oxidized LDL do not shut off when the cell has had enough cholesterol. Unlike the normal LDL receptors on most cells, which dial themselves down as cholesterol accumulates, these scavenger receptors keep working regardless of how engorged the cell becomes.4Journal of Leukocyte Biology. Macrophage scavenger receptors and foam cell formation The result is macrophages bloated with cholesterol, so packed with fat droplets that under a microscope they look foamy. These foam cells are the building blocks of an atherosclerotic plaque.5PubMed Central. Inhibition of LDL oxidation and oxidized LDL-induced foam cell formation in RAW 264.7 cells show anti-atherogenic properties of a foliar methanol extract of Scoparia dulcis
Foam cell formation is not the end of the inflammatory cascade. These dying, cholesterol-laden cells release signals that recruit more immune cells, which in turn take up more oxidized lipids and die, creating a self-reinforcing loop. Over years, this cycle builds a growing core of dead cells, cholesterol crystals, and debris inside the artery wall.
Not All Bad Cholesterol Particles Are the Same
A standard lipid panel gives you a single LDL-cholesterol number, but the reality is more granular. The particles that carry cholesterol through the bloodstream vary in size, density, and composition, and these differences affect how aggressively they promote atherosclerosis. Small, dense LDL particles are considered particularly harmful because they penetrate the artery wall more easily and are more susceptible to oxidation. All particles containing a protein called apolipoprotein B tend to promote plaque formation, but their individual potency differs based on their triglyceride content and other surface proteins.6Circulation. Atherogenic lipoprotein particles in atherosclerosis
This is why some researchers argue that measuring apoB, the protein present on every atherogenic particle, gives a better picture of cardiovascular risk than standard LDL-cholesterol alone. A review of head-to-head comparisons found that apoB outperformed LDL-cholesterol as a risk marker in every study that compared them directly.7PubMed. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk Two people can have identical LDL-cholesterol levels while one carries many more small, dense particles, each containing its own apoB molecule, and that person faces a higher risk of developing plaques.
Triglyceride-Rich Remnants and Lp(a)
LDL gets the most attention, but it is not the only lipid particle driving atherosclerosis. Triglyceride-rich lipoproteins and their remnants also contribute, sometimes in outsized ways. As the body breaks down large triglyceride-carrying particles, the leftover remnant particles become cholesterol-enriched. Those below a certain size can cross into the artery wall just like LDL, but individual remnant particles can carry up to four times as much cholesterol as a single LDL particle. Unlike LDL, remnant particles enter the artery wall faster than they leave, making their cholesterol deposition especially efficient.8European Heart Journal. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society This means that people with high triglycerides, even if their LDL looks acceptable, can still be accumulating cholesterol in their arteries at a worrying rate.
Then there is lipoprotein(a), commonly written as Lp(a). This particle is essentially an LDL particle with an extra protein attached, and it is one of the most frustrating risk factors in cardiology. Your Lp(a) level is almost entirely determined by genetics and barely budges with diet or exercise. A scientific statement from the American Heart Association identifies high Lp(a) as an independent and causal risk factor for atherosclerotic cardiovascular disease, acting through mechanisms that promote plaque formation, inflammation, and blood clotting.9PubMed Central. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association Most people have never had their Lp(a) tested because it is not part of a routine lipid panel, yet it was first recognized as a coronary risk factor over forty years ago.10PubMed Central. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options
The HDL Disappointment
For decades, HDL was presented as straightforwardly protective: the “good cholesterol” that ferries excess cholesterol out of artery walls and back to the liver for disposal. This process, called reverse cholesterol transport, is real. But the story fell apart when drug trials tried to exploit it. Multiple clinical studies that raised HDL-cholesterol levels with medications produced consistently disappointing results in terms of reducing heart attacks and strokes.11PubMed Central. Reverse cholesterol transport: current assay methods, alterations with disease and response to therapeutic intervention
The explanation that has emerged is that the amount of HDL cholesterol measured in a blood test does not reliably reflect how well HDL is actually functioning. An HDL particle that has been damaged by inflammation or oxidation may still register on a lab test but perform poorly at removing cholesterol from plaques.12PubMed Central. High-density lipoprotein function, dysfunction, and reverse cholesterol transport HDL-cholesterol concentration and HDL function turn out to have an inconsistent relationship, which is why simply pushing the number higher with a pill does not necessarily translate into less atherosclerosis.13PubMed Central. HDL and Reverse Cholesterol Transport The practical upshot for you: a high HDL level on your blood work is still a favorable sign in population studies, but it is not a shield you can count on the way a low LDL level is.
Familial Hypercholesterolemia as a Natural Experiment
Some of the strongest evidence for the causal link between lipids and atherosclerosis comes from people born with familial hypercholesterolemia, or FH. These individuals have a genetic defect that prevents their body from clearing LDL particles efficiently, leaving them with sharply elevated LDL from birth. All FH patients face a high risk of premature cardiovascular disease because of their lifelong exposure to elevated LDL.14PubMed. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels
The cardiovascular risk in FH goes beyond what you would predict from their cholesterol numbers alone. A large genetic study found that among people with LDL levels above 190 mg/dL, those who carried an FH-causing mutation had roughly a 22-fold higher risk of coronary artery disease compared to people with low LDL and no mutation. People with equally high LDL but without the mutation had about a 6-fold increase.15PubMed Central. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia The key difference is cumulative exposure: mutation carriers had been soaking their arteries in high LDL since childhood, while many of those without the mutation developed high levels later in life. The same study confirmed this by looking at serial lipid measurements over years. FH is, in effect, a natural experiment demonstrating that the longer your arteries are bathed in excess lipids, the worse the damage.
Why “Normal” Cholesterol Does Not Always Mean Safe
One of the most common misconceptions is that atherosclerosis only happens to people with obviously high cholesterol. In reality, most people who develop coronary artery disease do not have dramatically elevated LDL-cholesterol. Researchers noted decades ago that many patients with confirmed coronary disease had normal LDL-cholesterol but abnormally high levels of the LDL protein itself, suggesting they carried a larger number of small, cholesterol-poor particles that standard testing missed.16PubMed Central. Association of coronary atherosclerosis with hyperapobetalipoproteinemia
More recently, imaging studies have confirmed that subclinical atherosclerosis is startlingly common even in people with no traditional risk factors at all. A study using vascular imaging found that about half of participants who were free of standard risk factors still had detectable plaques or coronary artery calcification. Even in that group, LDL-cholesterol was independently associated with the presence and extent of atherosclerosis.17PubMed. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors The takeaway is that atherosclerosis exists on a spectrum. The process begins at LDL levels well below what most guidelines consider alarming, and it begins earlier in life than most people assume.
How Plaques Become Dangerous
A plaque that narrows an artery by 30 or 40 percent may never cause symptoms. The real danger comes when a plaque becomes unstable and ruptures. The most rupture-prone lesions have a specific architecture: a large core of dead cells and lipid debris, covered by an extremely thin fibrous cap. These thin-cap lesions are the ones that break open, exposing their contents to flowing blood and triggering the sudden formation of a clot that blocks the artery.18PubMed. Mechanisms of plaque formation and rupture19Cardiovascular Research. Biomechanical factors and macrophages in plaque stability
Animal studies tracking plaque development have shown that arteries where lipid deposits rapidly in the early months are the ones most likely to later develop these thin-cap, rupture-prone lesions.20EuroIntervention. The vulnerable artery: early and rapid deposition of lipid in coronary arteries is associated with subsequent development of thin-cap fibroatheromas Speed of lipid accumulation, not just total amount, appears to matter for how dangerous a plaque becomes.
Plaque rupture is the classic cause of a heart attack, but it is not the only one. Some acute events occur through a different mechanism called plaque erosion, where the surface lining of the plaque wears away without the cap actually cracking open. Eroded plaques tend to look different from ruptured ones and may involve distinct triggers.21PubMed Central. Plaque Erosion: A Distinctive Pathological Mechanism of Acute Coronary Syndrome The clinical distinction matters because future treatments may need to target both pathways rather than focusing solely on preventing rupture.
The Hidden Roles of Smooth Muscle and Macrophage Plasticity
The standard textbook picture of atherosclerosis casts smooth muscle cells as benign: they form the fibrous cap that protects the plaque from rupturing. Newer genetic tracing studies have complicated that picture. Smooth muscle cells in artery walls can undergo a kind of identity shift, losing their normal markers and taking on characteristics of macrophages or other cell types. These transformed smooth muscle cells can themselves become foam cells and drive inflammation, meaning they contribute to both building and destabilizing the plaque.22PubMed Central. Vascular Smooth Muscle Cells in Atherosclerosis The old assumption that smooth muscle cell activity in plaques is entirely protective turns out to be wrong.
Macrophages themselves are similarly plastic. During active plaque growth, the dominant macrophage population skews toward an inflammatory type. When conditions improve, as they do in animal models where cholesterol levels are aggressively lowered, the macrophage balance shifts toward a type associated with tissue repair and inflammation resolution.23PubMed Central. Dynamic Aspects of Macrophage Polarization during Atherosclerosis Progression and Regression However, this neat two-category framework is now considered an oversimplification; plaque macrophages exist across a much wider spectrum of states.24PubMed Central. Macrophages in Atherosclerosis Regression Understanding that spectrum is an active area of research, because treatments that nudge macrophages toward repair-promoting states could potentially shrink plaques even without large changes in blood lipid levels.
Beyond Cholesterol on the Blood Test
One finding that underscores how atherosclerosis is not purely a cholesterol problem is the role of clonal hematopoiesis, a condition where a mutation arises in blood-forming stem cells, causing a subset of immune cells to carry that mutation. In mouse experiments, animals prone to high cholesterol that received bone marrow with a specific mutation in a gene called Tet2 developed larger atherosclerotic lesions than controls. Their macrophages showed heightened activity of inflammatory genes that contribute to plaque growth.25PubMed Central. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease This means two people with identical lipid profiles can face different atherosclerosis risks based on mutations in their immune cells that no lipid panel would detect.
Diet also interacts with the lipid-atherosclerosis link in ways that are not as simple as popular messaging suggests. Saturated fat, for instance, raises LDL cholesterol through more than one mechanism, and the extent of the effect depends on context. In primate studies, the impact of saturated fat on LDL clearance from the blood was minimal when dietary cholesterol was low and the animal’s lipid profile was already normal. Saturated fat appeared to matter most as a compounding factor when other dietary excesses had already pushed the system into a hyperlipidemic state.26PubMed. Saturated fatty acids and LDL receptor modulation in humans and monkeys None of this means saturated fat is harmless, but it does mean its effect on atherosclerosis risk depends heavily on the metabolic backdrop against which it is consumed.
How Lipid-Lowering Treatments Target the Process
Statins remain the most widely used drugs for atherosclerosis prevention, and they attack the lipid-atherosclerosis connection at its root. They slow down the body’s production of cholesterol and also increase the number of LDL receptors on liver cells, pulling more LDL particles out of circulation.27PubMed Central. Understanding the molecular mechanisms of statin pleiotropic effects Beyond lipid lowering, statins appear to have anti-inflammatory and plaque-stabilizing effects, though researchers are still working out how much of their clinical benefit comes from cholesterol reduction versus these additional properties.
A newer class of drugs, PCSK9 inhibitors, works by a different route. Normally, a protein called PCSK9 tags LDL receptors on liver cells for destruction, which means fewer receptors are available to clear LDL from the blood. Blocking PCSK9 preserves those receptors, dramatically lowering LDL levels and reducing cardiovascular events.28PubMed Central. PCSK 9 Inhibitors: A Short History and a New Era of Lipid-lowering Therapy The success of these drugs provides yet another line of evidence that the connection between circulating lipids and atherosclerosis is causal: when you remove the lipid particles, the disease slows down. Trials targeting Lp(a) with newer RNA-based therapies are also underway, which could eventually help the roughly one in five people with genetically elevated Lp(a) levels who currently have no approved pharmacological option to lower them.